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INTRODUCTION
Temporal Lobe Epilepsy (TLE), the most common 
form of human partial epilepsy (Engel 2001), is poorly 
controlled by current antiepileptic pharmacotherapy 
(Cohen et al. 2003). Furthermore, despite a large body 
of experimental work, TLE epileptogenesis is still 
poorly understood. However, it has been shown that 
changes in GABAergic signaling play an important 
role in this regard (Cohen et al. 2003). Gamma-
Aminobutyric Acid (GABA), the main inhibitory neu-
rotransmitter in the adult central nervous system 
(CNS), at early developmental stages depolarizes target 
cells through an outwardly directed flux of chloride. In 
mature neurons, because of the low level of intracellu-
lar chloride ([Cl־] i), GABA triggers membrane hyper-
polarization due to passive influx of chloride down its 
electrochemical gradient. In contrast, immature neu-
rons have an elevated intracellular [Cl־]i, so that GABA 
triggers chloride efflux and membrane depolarization 
(Ben-Ari 2002). Two cation-chloride cotransporters 
may be especially important in controlling neuronal 
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[Cl־]i: the Na-K-2Cl cotransporter (NKCC1) loads neu-
rons with Cl- and favors depolarizing responses to 
GABA, whereas the K-Cl cotransporter (KCC2) nor-
mally extrudes Cl־ ions, promoting a hyperpolarizing 
response (Ben-Ari et al. 2007). In the adult brain, under 
pathophysiological conditions such as epilepsy and 
trauma, alterations in the balance of NKCC1 and KCC2 
activity may determine the switch from a hyperpolar-
izing to a depolarizing effect of GABA (Payne et al. 
2003). Various lines of evidence correlate epileptogen-
esis with altered functional expression of NKCC1 and 
KCC2 transporters. Woo et al. demonstrated that ani-
mals deficient in KCC2 exhibit frequent generalized 
seizures and die shortly after birth (Woo et al. 2002). 
Okabe and coauthors (2002) observed activity-depen-
dent increases in the mRNA of NKCC1, in the piriform 
cortex in a rat amygdala-kindling model. In addition, 
quantitative RT-PCR analyses of surgical specimens 
taken from the subiculum of patients with drug-resis-
tant temporal lobe epilepsy revealed upregulation of 
NKCC1 mRNA and down-regulation of KCC2 (Palma 
et al. 2006). Furthermore, in a study by Huberfeld and 
colleagues (2007) on biopsies from human epileptic 
tissue, perturbed chloride homeostasis and GABA-
ergic signaling was demonstrated, and Bumetanide at 
doses that selectively block NKCC1, suppressed inter-
ictal activity.
To design appropriate treatment strategies for these 
types of epilepsies, KCC2 and NKCC1 transporters 
should be considered as a target (Payne et al. 2003). 
Brain-derived neurotrophic factor (BDNF) is one of the 
underlying players in the regulation of KCC2 expression. 
Aguado and coworkers (2003) indicated that BDNF act-
ing via tyrosine kinase B receptor (TrkB) can increase 
KCC2 expression during early development in embryos, 
and in a recent study, Mao and others (2011) showed a 
novel BDNF/TrkB signaling pathway that profoundly 
affects neuronal chloride homeostasis. On the other hand, 
it has been shown by Fukuchi and colleagues (2009). that 
TrkB receptor of BDNF plays an important role in epilep-
togenesis. In addition, in a study by Rivera and coauthors 
(2004) KCC2 expression in mature central neurons was 
downregulated by BDNF, indicating two modes of 
BDNF-mediated regulation of KCC2 expression. 
Recently, Shulga and others (2008) reported that 
BDNF increases KCC2 mRNA levels in axotomized cen-
tral neurons indicating that injured neurons reverse their 
response to this neurotrophin by switching the BDNF-
induced downregulation of KCC2 to upregulation.
Considering the altered functional expression of 
KCC2/NKCC1 transporters in temporal lobe epilepsy 
and the role of BDNF in the regulation of KCC2 
expression during development and CNS injury we 
assessed the possible contribution of BDNF on KCC2/
NKCC1 expression, ictogenesis and behavioral altera-
tions in a rat model of temporal lobe epilepsy. 
METHODS
Animals
Adult male Wistar rats weighing 250–270 g were 
purchased from Tehran Pasteur Institute and housed in 
a controlled environment (07:00 am/07:00 pm light/
dark cycle; 22±1°C), two weeks before the start of 
experiments. They had free access to food and water. 
All experiments were performed in accordance with 
the Helsinki declaration, and the experiments were 
approved by the ethical committee of Iran University 
of Medical Sciences (#1090).
Pilocarpine-induced Epilepsy
Pilocarpine hydrochloride (Sigma, 350 mg/kg), a 
muscarinic cholinergic agonist, was administered 
intraperitonealy (ip) to induce Status Epilepticus (SE). 
Animals were pretreated with the cholinergic antago-
nist scopolamine methyl nitrate (Sigma, 1 mg/kg, ip) 
30 minutes before the pilocarpine injection to reduce 
peripheral cholinergic effects (Ferhat et al. 2003). The 
animal’s behavior was observed for several hours 
thereafter, and scored according to Racine’s classifica-
tion (Racine 1972). Only rats that displayed SE (stages 
3–5) for 3–4 hours were selected, and this period of 
robust seizures was terminated by a single injection of 
diazepam (7 mg/kg, ip). Animals were hand fed after 
SE until they could eat and drink on their own. Age-
matched naive rats or animals receiving a saline injec-
tion instead of pilocarpine were used as controls. Since 
there was no difference between control groups, data 
from both groups were pooled (Table I). 
Monitoring of animals for spontaneous 
recurrent seizures
Two weeks after pilocarpine injection, all rats were 
video monitored for 12 weeks (8 hours/day, 5 days/
week) to record spontaneous seizures. 
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stereotaxic surgery
Five days before the pilocarpine injection, animals 
of treatment groups were placed in a stereotaxic frame, 
under ketamine (87 mg/kg ip) and xylazine (13 mg/kg 
ip) anesthesia. A guide cannulae was implanted in the 
dorsal hippocampus (coordinates: 1.5 mm lateral and 
1.7 mm posterior to bregma, 3.0 mm deep from dura) 
according to Pellegrino and Cushman atlas (1979). 
bDNF injection in vivo
The treatment group was divided into two sub-
groups (n=9 each): One group received multiple 
Table I
Animal Groups tested in this study
Groups
Seizure
Condition BDNF treatment
Number of animals and post-SE survival time
Biochemistry1 Behavior and chronic seizure2
Number Post-SE survival Number Post-SE survival
Control3 (naive) No No 5 Not applicable 6 Not applicable
Seizure model Pilocarpine No 7 1wk (n=2) 4
2wk (n=2) 5
 2wk (n=3) 5,6
6 12 wk
Sham3 Saline
(pilocarpine 
solvent)
No 3 Not applicable 6 Not applicable
Treatment 
multiple injections
Pilocarpine Multiple BDNF 
injections
3 2 wk 6 12 wk
Treatment
single injection
Pilocarpine Single BDNF 
injection
3 2 wk 6 12 wk
Control for treatment
multiple injections6
Pilocarpine Multiple PBS 
(BDNF solvent) 
injections
3 2 wk 6 12 wk
Control for treatment
single injection 6
Pilocarpine Single PBS  
(BDNF solvent) 
injection
3 2 wk 6 12 wk
1Right and Left hippocampi of the same animals were used for Western-Blot and Real Time RT-PCR tests, respectively; 
2Six animals from each group underwent video monitoring for spontaneous seizure detection as well as post-SE 
hyperexcitability tests, which were performed from 2nd week to 12th weeks post-SE; 3Their data were pooled together, 
because there was no difference between them; 4To evaluate changes in KCC2 expression after SE, we decapitated 
pilocarpine treated animals at two time points (7th day and 14th day) after SE (Fig. 1); 5 Five pilocarpine treated animals 
were decapitated 14 days after SE, n=2 were used to evaluate changes in KCC2 expression after SE (Fig. 1) and n=3 were 
used to evaluated effect of BDNF treatment (Figs 2–4); 6Their data were pooled together, because there was no difference 
between them.
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BDNF microinjections (Sigma, Concentration: 1 µg/
µl, Injection volume: 2.5 µl, was injected 4 times at 
days 10, 11, 12, 13 after status epileticus), while the 
other group was administered with a single high-
dose of BDNF (Sigma, Concentration: 1 µg/µl, 
Injection volume: 10 µl, injected at day 13 after status 
epileticus). Age-matched epileptic rats received the 
same amount of BDNF solvent, Phosphate Buffered 
Saline (PBS), as control. All of the injections were 
bilateral. Since there was no difference between 
these controls and the model group (epileptic rats 
without treatment), their data were pooled together 
(Table I). 
behavioral evaluation
One week after status epilepticus, 6 rats from each 
group were evaluated in different hyperexcitability 
tests. All tests were performed twice weekly for 12 
weeks. According to previous studies, pilocarpine-
treated epileptic animals are more easily agitated com-
pared to normal animals (Rice et al. 1998). A post-
seizural Behavior Battery (PSBB) of tests described by 
Rice and coauthors (1998) was used to discriminate 
hyperexcitability differences between groups.
Approach-response test
A pen held vertically is moved slowly toward the 
face of the animal. Responses were recorded as 1 – no 
reaction; 2 – the rat sniffs at the object; 3 – the rat 
moves away from the object; 4 – the rat freezes; 5 –the 
rat jumps away from the object; and 6 – the rat jumps 
at or attacks the object.
Touch-response test
The animal is gently prodded in the rump with the 
blunt end of a pen. Responses were recorded as 1 – no 
reaction; 2 – the rat turns toward the object; 3 – the rat 
moves away from the object; 4 – the rat freezes; 5 – 
the rat turns toward the touch; 6-the rat turns away 
from the touch; and 7 – the rat jumps with or without 
vocalizations.
Finger-snap test
A finger snap several inches above the head of the 
animal is performed. Responses were recorded as 1 – 
no reaction; 2 – the rat jumps slightly (normal reac-
tion); and 3 – the rat jumps dramatically.
Pick-up test
The animal is picked up by grasping it around the 
body. Responses were recorded as 1 – very easy; 2 – 
easy with vocalizations; 3 – some difficulty, the rat 
rears and faces the hand; 4 –  the rat freezes; 5 – dif-
ficult, the rat avoids the hand by moving away; and 6 
– very difficult, the rat behaves defensively, and may 
attack the hand.
These tests were done by three independent observ-
ers; the means of their scores were calculated for each 
animal for each test. The tests were performed in the 
home cage with 30 minutes interval between each test.
Western blot
Western blotting was performed on hippocampal 
extracts from different groups. For detecting KCC2 
and NKCC1 proteins separately, hippocampal tissue 
Fig. 1. Gradual down-regulation of KCC2 protein after pilo-
carpine induced status epilepticus (SE): KCC2 protein 
expression was analyzed in post-mitochondrial supernatant 
obtained from whole hippocampal homogenates of control, 
1-week post-SE and 2-week post-SE animals. Expression of 
KCC2 monomer (130–140 kDa) was normalized to the beta-
actin (KCC2/Actin) and then plotted as percentage of con-
trol protein levels in the histogram comparing groups. Each 
column represents mean ± SEM. Western blot analysis 
showed that KCC2 protein expression is decreased signifi-
cantly on days 7th and 14th post-SE.  (*P<0.05, **P<0.01 
by one-way ANOVA with post-hoc Tukey Test) [n=2 per 
group, 2 western blot experiments per animal (Means from 
the two experiments were taken as a result for one ani-
mal)].
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was homogenized and immediately divided into two 
equal-volume aliquots. Briefly, the samples were 
homogenized in Radioimmunoprecipitation Assay 
(RIPA) buffer [150 mM NaCl, 0.5% sodium deoxy-
cholate, 0.1% SDS (sodium dodecyl sulphate), 50 mM 
Tris-HCl pH 7.5], supplemented with a protease inhib-
Fig. 2. (A) Representative image of KCC2 western blot for the 4 groups. KCC2 protein expression was analyzed in post-
mitochondrial supernatant obtained from whole hippocampal homogenates of different groups, and it was shown that mono-
meric KCC2 levels were rescued by BDNF in hippocampi after temporal lobe epilepsy, but the bands representing KCC2 
dimers were below the level of detection in both treated groups. The 130–140 kDa and the >200 kDa bands correspond to 
the monomeric and oligomeric proteins, respectively. Beta-actin (~42 kDa) was used as a control. (B) Quantification of 
KCC2 expression in epileptic rats normalized to controls. The expression of KCC2 was normalized to beta-actin (KCC2/
Actin) and then plotted as percentage of control comparing groups. Each column represents mean ± SEM. BDNF induced a 
significant increase in monomeric KCC2 levels when administered either as a single or multiple injections compared to 
epileptic untreated controls 14 days post-SE. Treating with BDNF resulted in higher KCC2 levels than in control animals 
(**P<0.01, ***P<0.001 by one-way ANOVA with post-hoc Tukey Test) (n=3 per group, and 2 experiments per animal). 
Groups: control: control rats; 14th day post-SE: post-SE rats that did not receive BDNF, and were sacrificed at 14th day 
post-SE; single high dose BDNF injection: post-SE rats that received 10 µg BDNF as a single dose, and were sacrificed at 
14th day post-SE; multiple BDNF injections: post-SE rats that received four times 2.5 µg of BDNF injections, and were 
sacrificed at 14th day post-SE.
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itor cocktail (Pierce), then centrifuged at 14 000 g for 
20 minutes at 4°C. The supernatant was transferred to 
a new tube and protein concentration was determined 
by the Bradford protein assay kit (Pierce).  Equal 
amounts of protein samples (KCC2: 30 mg, NKCC1: 
100 mg) and pre-stained protein ladder (Pierce) were 
electrophoretically (Bio-Rad)  separated on 8% SDS 
polyacrylamide gels, and transferred to a Polyvinylidene 
Difluoride  (PVDF)  membrane. The blots were incu-
bated in 5% skimmed milk in Tris-Buffer Saline 
Tween20 (TBST)  for 1 hour at room temperature, and 
then incubated overnight with a primary antibody 
(abcam, Rabbit polyclonal anti-KCC2 and anti-NKCC1 
antibodies  1/1 000 and 1/4 000, respectively) at  4°C. 
The blots were rinsed with TBST three times and incu-
bated with horseradish peroxidase-conjugated goat 
polyclonal secondary antibody to rabbit Ig for 1 hour. 
After washing with TBST, protein bands were visual-
ized using the enhanced chemiluminescence assay 
(ECL, Amersham). Quantitative measurement of 
KCC2 and NKCC1 protein bands was performed with 
UVIdoc software, and beta-actin was used as control.
Real-time reverse transcription polymerase 
chain reaction 
Real-time RT PCR was performed on hippocampal 
extracts from different groups (n=3 for each group). 
Briefly, total cellular mRNA was isolated using QIAzol 
(Qiagen) according to the manufacturer’s protocol, 
which subsequently underwent cDNA synthesis by 
reverse transcriptase (Vivantis Cat No: RTPL12). 
HPRT1 (Hypoxanthine Phosphoribosyltransferase 1) 
was utilized as housekeeping gene. Specific primers 
for rat KCC2 were purchased from Qiagen. Gene 
expression levels were measured by Rotor Gene 6 000 
(Corbett, Concorde, NSW, Australia). We calculated 
relative expression ratio using the Relative  Expression 
Software Tool 2009 (REST).  
Statistical analyses
For the Western blot experiments, statistical com-
parisons among the groups were performed by one-
way analysis of variance (ANOVA) followed by the 
post-hoc Tukey HSD for individual differences.  The 
significance of differences in behavioral parameters 
within each group was analyzed by using repeated-
measures ANOVA. Multiple comparison of post hoc 
analysis was considered using Bonferroni adjustment 
method.  The level of significance was set at P<0.05. 
Relative expression software tool (REST) was used for 
statistical analysis of relative expression results in real-
time PCR (Pfaffl et al. 2002)
RESULTS
KCC2 protein levels decrease after Status 
Epilepticus
To follow the time course of KCC2 changes after 
SE, we used Western blot analysis to compare KCC2 
levels at two time points post-SE. KCC2 levels were 
significantly decreased at one and two weeks post-SE 
to 62% (P<0.05) and 45% (P<0.01) of control, respec-
tively (Fig. 1).  
Effect of bDNF treatment on KCC2 expression
BDNF regulates expression of KCC2 through its 
TrkB receptor (Ben-Ari et al. 2007). We administered 
BDNF to the dorsal hippocampus (single dose: 10 µg, 
Fig. 3. BDNF treatment rescues KCC2 mRNA expression. 
Values of KCC2 mRNA are presented as average changes in 
KCC2 mRNA normalized to average control values.  # indi-
cates significance according to REST 2009 software. Groups 
(n=3 per group): control: control rats; 14th day post-SE: 
post-SE rats that did not receive BDNF, and were sacrificed 
at 14th day post-SE; single high dose BDNF injection: post-
SE rats that received 10 µg BDNF as a single dose, and were 
sacrificed at 14th day post-SE; multiple BDNF injections: 
post-SE rats that received four times 2.5 µg of BDNF injec-
tions, and were sacrificed at 14th day post-SE.
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or four doses: 2.5 µg each) during latent phase of 
pilocarpine-induced temporal lobe epilepsy. Three 
animals in each group were decapitated 14 days post-
SE, and Western blotting and real-time RT PCR quan-
tified KCC2 expression. 
KCC2 Protein Expression
 We found that in both treated groups, expression of 
KCC2 monomeric bands increased markedly (P<0.001) 
compared to untreated epileptic animals. BDNF treat-
ment resulted in higher KCC2 levels than in control 
animals (Fig. 2). Interestingly, after both single and 
multiple injections of BDNF the bands representing 
KCC2 dimers were below the level of detection, indi-
cating that a profound decrease of this oligomeric form 
occurred. 
KCC2 mRNA Expression
KCC2 mRNA underwent a significant decrease in 
pilocarpine-treated animals compared to controls. 
Both single high dose and multiple injections of BDNF 
rescued KCC2 mRNA levels, which, after multiple 
Fig. 4. (A) Representative image of NKCC1 western blot for the 4 groups. NKCC1 protein expression was analyzed in post-
mitochondrial supernatant obtained from whole hippocampal homogenates of different groups, and β-actin was used as a 
control. (B) Quantification of NKCC1 expression in epileptic rats normalized to controls. The expression of NKCC1 was 
normalized to beta-actin (NKCC1/Actin) and then plotted as percentage of control. NKCC1 protein expression was signifi-
cantly higher the 2-week post-SE animals than normal controls which was resuced by single high dose injection of BDNF. 
(***P<0.001 by one-way ANOVA with post-hoc Tukey Test) (n=3 per group, and 2 experiments per animal). Groups: con-
trol: control rats; 14th day post-SE: post-SE rats that did not receive BDNF, and were sacrificed at 14th day post-SE; single 
high dose BDNF injection: post-SE rats that received 10 µg BDNF as a single dose, and were sacrificed at 14th day post-SE; 
multiple BDNF injections: post-SE rats that received four times 2.5 µg of BDNF injections, and were sacrificed at 14th day 
post-SE.
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BDNF injections, were significantly higher than in 
control animals (Fig. 3).
Contribution of bDNF to NKCC1 expression
NKCC1 expression in the hippocampus of the ani-
mals from different groups was compared on the 14th 
day post-SE via Western-blotting (n=3 each). We 
observed a significant upregulation of NKCC1 protein 
levels in epileptic rats at this time point compared to 
control animals (P<0.001). Single injection of a high 
dose of BDNF resulted in a significant decrease in 
NKCC1 protein levels compared to the untreated epi-
leptic rats (P<0.001), but multiple BDNF injections did 
not change NKCC1 expression (Fig. 4).
behavioral alterations in epileptic rats
According to our general observations, pilocarpine 
treated rats were more easily startled than control ani-
mals, but after BDNF treatment (either single or mul-
tiple injection) we were able to handle them comfort-
ably at least for one week.  
The PSBB was done at several time points after SE 
to determine the behavioral changes in epileptic rats 
and the effect of BDNF treatment in this regard (n=6 
for each group). When we compared pilocarpine-in-
jected animals with the control group on the 7th day 
post-SE, a significant difference (P<0.05) was observed 
in the touch-response and pick-up tests, indicating that 
epileptic rats are more sensitive to environmental 
Fig. 5. Post-seizure behavioral changes 1,2 and 6 weeks post-SE: (A) Touch-Response; (B) Pick-up; (C) Finger-Snap; (D) 
Approach-Response. A significant difference was observed in the touch-response and pick up tests between pilocarpine 
injected animals and control group at 7th day post-SE (*P<0.05, independent sample t test). Within group comparisons 
indicated that BDNF treatment can ameliorate hyperexcitability behaviors for a short period of time (*P<0.017, Bonferroni 
corrected). Groups (n=6 per group): control: control rats; 14th day post-SE: post-SE rats that did not receive BDNF, and were 
sacrificed at 14th day post-SE; single high dose BDNF injection: post-SE rats that received 10 µg BDNF as a single dose, 
and were sacrificed at 14th day post-SE; multiple BDNF injections: post-SE rats that received four times 2.5 µg of BDNF 
injections, and were sacrificed at 14th day post-SE.
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stimuli. BDNF treatment counteracted these behaviors 
on the 14th day post-SE, but this effect lasted only 1 to 
2 weeks, and these test scores gradually returned 
towards baseline (pre-treatment period) (Fig. 5).
Spontaneous recurrent seizures detection
The earliest spontaneous seizure was observed 2 to 
3 weeks post-SE in the untreated epileptic group. All 
except one of these animals had 1 to 3 spontaneous 
seizures per week during the video monitoring period. 
In the two BDNF-treated groups the onset of spontane-
ous seizures was 4 to 6 weeks post-SE. All the animals 
of the treated groups had 1 to 3 spontaneous seizures 
per week, which was not different from the untreated 
group. These data indicate that BDNF treatment can 
delay epileptogenesis, but is not sufficient in prevent-
ing spontaneous seizure generation (n=6 for each 
group).   
DISCUSSION
Various lines of evidence indicate that BDNF, a 
member of the neurotrophin family of growth factors 
(Leibrock et al. 1989), is associated with increased 
neuronal activity (Tanaka et al. 1997), and has been 
considered as a proepileptogenic factor (Rivera et al. 
2004). On the other hand, according to several reports, 
the development of epilepsy can be attenuated or post-
poned by intrahippocampal delivery of BDNF 
(Koyama and Ikegaya 2005, Paradiso et al. 2009). To 
address these contrasting effects of BDNF, it is essen-
tial to clarify TLE pathogenesis. While no definitive 
evidence exists to support a single mechanism for 
temporal lobe epileptogenesis, a large body of evi-
dence suggests that depolarizing GABAergic signal-
ing accompanied by altered expression of the chloride 
co-transporters KCC2 and NKCC1 contributes to epi-
leptiform activity in animal models of epilepsies as 
well as human epileptic tissues (Cohen et al. 2002, 
Dzhala et al. 2005, Palma et al. 2006, Huberfeld et al. 
2007, Munoz et al. 2007, Pathak et al. 2007).  In this 
study we showed that there is a notable imbalance 
between expression of the two chloride transporters in 
an animal model of TLE. NKCC1 expression was 
markedly increased, while that of KCC2 was signifi-
cantly reduced in epileptic hippocampi compared to 
intact controls. This alteration in the expression of 
chloride transporters together with a depolarizing, 
immature-like response of GABA is in line with other 
pathophysiological conditions such as neuronal trau-
ma, axotomy and spinal cord injury (Nabekura et al. 
2002, Payne et al. 2003, Shulga et al. 2008, Boulenguez 
et al. 2010, Ziemlinska et al. 2014). The depolarizing 
GABA-A mediated response during development is 
due to chloride uptake mediated by NKCC1, and the 
hyperpolarizing response in mature neurons is detect-
able when KCC2 expression increases causing a [Cl-]i 
reduction (Rivera et al. 1999). Accumulating evidence 
indicate that upregulation of KCC2 is induced by 
BDNF leading to the functional maturation of GABA-A 
mediated responses (Aguado et al. 2003, Carmona et 
al. 2006, Ludwig et al. 2011). Ludwig and coauthors 
(2011) demonstrated that BDNF activates expression 
of the immediate early growth response 4 gene by 
induction of the TrkB/mitogen activated protein kinase 
pathway which stimulates KCC2b promoter activity. 
Furthermore, KCC2 expression is lower in the hip-
pocampus of mice which are deficient in TrkB 
(Carmona et al. 2006). On the other hand, in adult 
normal cortical neurons BDNF downregulates KCC2 
expression (Rivera et al. 2004) indicating two modes 
of BDNF-mediated regulation of KCC2 expression: 
upregulation during development and downregulation 
in mature central neurons (Shulga et al. 2008). 
Interestingly, Shulga and colleagues (2008) investi-
gated the role of BDNF on KCC2 expression of axoto-
mized corticospinal neurons, and demonstrated that 
injury activates a developmental-like mode of BDNF-
mediated effects inducing a switch in the effect of 
BDNF on KCC2 expression from downregulatory to 
upregulatory. Furthermore, Boulenguez and cowork-
ers (2010) showed that while KCC2 is downregulated 
after spinal cord injury in rats, intrathecal injection of 
BDNF (10 µg) can upregulate KCC2 expression 15 
days after the injury. 
Considering the results of the two recent studies 
(Shulga et al. 2008, Boulenguez et al. 2010), we inves-
tigated the effects of intra-hippocampal injection of 
BDNF on KCC2 expression during the second post-SE 
week. Our results showed that application of either a 
single or multiple doses of BDNF, up-regulated KCC2 
expression. While the results we obtained with the 
single injection of BDNF are in accordance with the 
findings of Boulenguez and coworkers (2010), in a 
recent study by Ziemlinska and others (2014) long 
term BDNF treatment reduced KCC2 expression after 
a complete transection of the spinal cord. 
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As shown in Figure 2, during the first 24 hours 
post BDNF injection, monomeric KCC2 is prevailing 
while oligomeric KCC2 was below the level of detec-
tion. Blaesse and colleagues (2006) showed that age-
dependent KCC2 oligomerization occurs throughout 
the nervous system development, because mono-
meric KCC2 which is inactive for transport requires 
oligomerization to be active. Furthermore, they 
showed that the developmental shift of GABA from 
depolarizing to hyperpolarizing occurs over several 
days, and this shift can be determined by both 
increased gene expression and KCC2 oligomeriza-
tion. One possible explanation for this finding is that 
BDNF stimulates KCC2 synthesis and storage, but 
downregulates its oligomerisation.
Our behavioral studies revealed that hyperexcitabil-
ity behaviors of animals were ameliorated for a short 
period of time after BDNF treatment. Furthermore, 
development of spontaneous recurrent seizures was 
delayed but not prevented in BDNF-treated animals, 
suggesting that in this study, an injection of BDNF 
delayed epileptogenesis. This effect might stabilize for 
a longer period of time if rats were infused continu-
ously with BDNF using osmotic minipumps. On the 
other hand, given the disappearance of oligomeric 
KCC2, these transient behavior improvements might 
be due to  BDNF effects on neurogenesis and embank-
ing neuronal damage (Paradiso et al. 2009).
Another interesting finding of the present study 
was the reduction of NKCC1 expression by a single 
high dose of BDNF. To the best of our knowledge, 
this is the first time there is a direct effect of BDNF 
on NKCC1 expression. Further studies are warranted 
to determine why only a high dose injection but not 
multiple injections of BDNF altered NKCC1 expres-
sion. 
CONCLUSION
While recent studies point to NKCC1 inhibition as a 
promising strategy for TLE treatment (Huberfeld et al. 
2007, Brandt et al. 2010, Eftekhari et al. 2013), an 
increase in KCC2 expression can be considered as an 
alternative treatment to Bumetanide application. In a 
recent study, Gagnon and others (2013). showed that 
enhancing KCC2 activity can be the favored therapeu-
tic strategy to restore inhibition and normal function in 
pathological conditions involving impaired chloride 
transport.
If we want to focus on KCC2 activation as a TLE 
treatment strategy it is essential to find out for how 
long after induction of TLE, BDNF manages to upreg-
ulate KCC2, keeping its immature-state function. On 
the other hand, as applying exogenous BDNF is not 
practical and amenable for human patients future 
experiments are needed to modify KCC2 expression 
via endogenous BDNF. Although, Shulga and coau-
thors (2008) mentioned in their study that the endoge-
nous levels of BDNF were not enough to upregulate 
KCC2, more recent studies point to an up-regulation of 
endogenous BDNF by application of some hormones 
like tyroxine (Shulga et al. 2009) and statins like sim-
vastatin (Han et al. 2011) in injured neurons. Future 
studies are warranted to assess any possible therapeu-
tic effects of such agents on temporal lobe epilepsies 
via inducing endogenous BDNF.
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